Gilead Sciences | GILD - Gross Profit On Sales

Stock Price
130.83
Daily Change
1.16 0.89%
Monthly
-3.71%
Yearly
23.24%
Q2 Forecast
126.98

Gilead Sciences reported $5.52B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
ALKERMES USD 331.33M 7M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amgen USD 6.89B 415M Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Coherus Biosciences USD 8.7M 853K Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Incyte USD 1.17B 217.51M Mar/2026
J&J USD 17.24B 642M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Moderna USD -566M 792M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 10.07B 184M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
United Therapeutics USD 315.5M 286.6M Dec/2025
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026